| Methods |
2‐ to 4‐week placebo run‐in; inclusion criteria=sitting DBP 95‐115 mm Hg and SBP < 180 mm Hg after run‐in; 12‐week total double‐blind treatment, 4‐week double‐blind treatment at initial fixed dose, non‐responders were up‐titrated after 4 weeks |
| Participants |
Valsartan 80 mg: n=364(144 males,220 females); mean age=53.5(11.1) years; baseline sitting SBP=153.9(14.9) mm Hg, DBP=101.0(4.5) mm Hg;
Placebo: n=183(113 males,70 females); mean age=54.0(11.8) years; baseline sitting SBP=154.0(15.0) mm Hg, DBP=101.3(4.6) mm Hg |
| Interventions |
Valsartan 80 mg once daily;
Placebo;
administered at approximately 8 AM |
| Outcomes |
Least mean square change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
Used week 4 BP data only; BP change reported, SD of change not reported, endpoint BP and SD not reported; imputed SBP SD of change from baseline SBP SD of change, imputed overall trial mean DBP SD of change; SBP data from Figure 1, p. 487, DBP data from text, p. 485; Jadad score=2; funding source= Ciba‐Geigy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
